Safety and Efficacy of Perispinal Etanercept for Chronic Stroke
This study provides Class I evidence that in patients with imaging-confirmed ischemic or hemorrhagic stroke, perispinal etanercept (25 mg) injection does not improve the patients' quality of life 28 days after injection.
Authors
- Geoffrey Cloud (ORCID: https://orcid.org/0000-0002-8365-6907)
- Leonid P. Churilov (ORCID: https://orcid.org/0000-0002-9807-6606)
- Nigel Gilchrist (ORCID: https://orcid.org/0009-0003-8907-8129)
- Julie Bernhardt (ORCID: https://orcid.org/0000-0002-2787-8484)
- Marion Walker (ORCID: https://orcid.org/0000-0002-3534-591X)
- J.K. Ho
- Vincent Thijs (ORCID: https://orcid.org/0000-0002-6614-8417)
- Nikola Sprigg (ORCID: https://orcid.org/0000-0002-5871-8168)
- Brooke Parsons
- Philip M. Bath (ORCID: https://orcid.org/0000-0003-2734-5132)
- Vimal Stanislaus
- Forum Tilvawala (ORCID: https://orcid.org/0009-0007-1209-3880)
- Lara Ruthnam (ORCID: https://orcid.org/0009-0009-4526-3895)
Institutions
- The Royal Melbourne Hospital (AU)
- University of Nottingham (GB)
- The University of Melbourne (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- Christchurch Clinical Studies Trust (NZ)
- Alfred Health (AU)
- Austin Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Neurology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1212/wnl.0000000000213981
- Citations
- 1
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Amgen
- AtriCure
- Australian Government
- Inselspital, Universitätsspital Bern
- National Institute for Health and Care Research
- Centre Hospitalier Universitaire Vaudois
- Allergan
- National Health and Medical Research Council